Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eflornithine + sulindac
- Development stage
- Unknown
- Lead developer
- Panbela Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Eflornithine + sulindac is an orally administered combination therapy under development primarily for the treatment of familial adenomatous polyposis (FAP). Eflornithine (also known as difluoromethylornithine or DFMO) acts by inhibiting ornithine decarboxylase, thereby reducing levels of polyamines that promote adenoma growth. Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) that blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), permitting apoptotic signaling and activating SSAT to expel polyamines from intestinal cells. The combination targets two different pathways involved in polyp formation and progression. Developed by Panbela Therapeutics, this therapy has been evaluated in phase III clinical trials for FAP and is also being studied for prevention of recurrence of high-risk adenomas and second primary colorectal cancers in patients with stage 0–III colon or rectal cancer[1][4][5][6].
- Brand names
- Flynpovi
- Other names
- difluoromethylornithine + sulindacDFMO + sulindacCPP-1X + sulindac
02
Targets
ODC1 (Ornithine decarboxylase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)SAT1 (Spermidine/spermine N1-acetyltransferase 1)PGHS-1 (Prostaglandin G/H Synthase 1)PDE6 (Phosphodiesterase 6)
Beyond the preview
Go deeper on Eflornithine + sulindac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eflornithine + sulindac.